XORTX Therapeutics Inc. (XRTX) 10-Year Financial Performance & Capital Metrics

XRTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutXORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.Show more

Revenue $0
EBITDA -$4M +41.2%
Net Income -$5M -116.8%
EPS (Diluted) -1.65 -52.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -119.41% -215.6%
ROIC -255.76%
Debt/Equity 0.01 +368.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 45.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-198.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM-214.13%

ROCE

10Y Avg-181.3%

5Y Avg-106.43%

3Y Avg-74.29%

Latest-84.46%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	19.32K	15.35K	16.04K	14.14K	55.52K	142.25K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-19.32K	-15.35K	-16.04K	-14.14K	-55.52K	-142.25K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	0.21%	-0.05%	0.12%	-2.93%	-1.56%	1%
Operating Expenses+	36.92K	405.34K	464.07K	1.16M	421.1K	1.08M	2.87M	9.82M	6.01M	3.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	36.92K	389.31K	380.92K	795.65K	390.33K	861.93K	2.2M	3.32M	3.55M	3.33M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	66.37K	342.25K	30.77K	217.78K	674.48K	6.5M	2.46M	264.29K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-2.64M	0	0	0	0	0	0
Operating Income+	-36.92K	-405.34K	-469.44K	-1.16M	-436.45K	-1.1M	-2.89M	-9.87M	-6.16M	-3.59M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-9.98%	-0.16%	-1.47%	0.62%	-1.51%	-1.63%	-2.42%	0.38%	0.42%
EBITDA+	-36.92K	-389.31K	-452.67K	-1.14M	-421.1K	-1.08M	-2.87M	-9.82M	-6.01M	-3.54M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-9.54%	-0.16%	-1.51%	0.63%	-1.56%	-1.66%	-2.42%	0.39%	0.41%
D&A (Non-Cash Add-back)	0	16.02K	16.78K	19.32K	15.35K	16.04K	14.14K	55.52K	142.25K	55.71K
EBIT	0	-405.34K	-443.88K	-1.09M	-456.81K	-997.72K	-1.3M	-7M	-2.2M	-3.76M
Net Interest Income+	0	0	0	0	-28.7K	-10.61K	-4.43K	101.49K	258.19K	175.26K
Interest Income	0	0	0	0	0	0	0	101.37K	257.65K	175.26K
Interest Expense	0	8.63K	15.46K	22.3K	37.21K	13.51K	4.39K	0	0	0
Other Income/Expense	0	-25.52K	-47.09K	-2.71M	-49.05K	87.43K	1.58M	2.88M	3.96M	-1.17M
Pretax Income+	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	8.63K	10.09K	22.3K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-10.24%	-0.14%	-6.96%	0.87%	-1.08%	-0.3%	-4.36%	0.69%	-1.17%
Net Income (Continuing)	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.49	-2.05	-2.24	-6.45	-1.06	-1.73	-1.19	-4.72	-1.08	-1.65
EPS Growth %	-	-3.18%	-0.09%	-1.88%	0.84%	-0.63%	0.31%	-2.97%	0.77%	-0.53%
EPS (Basic)	-0.49	-2.05	-2.24	-6.45	-1.06	-1.73	-1.19	-4.72	-1.08	-1.65
Diluted Shares Outstanding	75.57K	202.74K	211.45K	584.99K	595.49K	740.45K	1.09M	1.48M	1.98M	2.88M
Basic Shares Outstanding	75.57K	202.74K	211.45K	584.99K	595.49K	740.45K	1.09M	1.48M	1.98M	2.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.94K	18.34K	63.55K	979.65K	815.25K	1.61M	20.12M	10.87M	4.07M	2.68M
Cash & Short-Term Investments	762	16.77K	61.94K	260.02K	58.61K	134.31K	18.8M	10.41M	3.45M	2.47M
Cash Only	762	16.77K	61.94K	260.02K	58.61K	134.31K	18.8M	10.41M	3.45M	2.47M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	10.17K	0	0	30.26K	0	11.25K	0	81.75K	60.71K	17.64K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	247.94K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	636.18	-
Other Current Assets	0	0	1.61K	689.37K	750.14K	0	764.31K	0	0	0
Total Non-Current Assets+	169.15K	264.13K	427.06K	285.59K	272.73K	183.75K	1.86M	1.48M	1.4M	1.42M
Property, Plant & Equipment	169.15K	0	1.12K	731	341	0	0	92.49K	23.93K	34.72K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	264.13K	258.71K	284.86K	272.39K	183.75K	255.59K	199.43K	175.25K	183.11K
Long-Term Investments	0	0	0	0	0	0	0	1.61M	1.58M	0
Other Non-Current Assets	0	0	167.22K	0	0	0	1.6M	1.18M	1.2M	1.2M
Total Assets+	180.09K	282.46K	490.6K	1.27M	1.09M	1.8M	21.98M	12.34M	5.47M	4.09M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.57%	0.74%	1.58%	-0.14%	0.65%	11.24%	-0.44%	-0.56%	-0.25%
Total Current Liabilities+	60.16K	599.52K	1.11M	900.45K	1.3M	811.04K	699.22K	1.51M	294.94K	757.99K
Accounts Payable	27.59K	159.67K	331.36K	304.5K	607.39K	305.83K	409.66K	1.29M	195.81K	84.02K
Days Payables Outstanding	-	-	-	5.75K	14.45K	6.96K	10.58K	8.5K	502.42	-
Short-Term Debt	0	124.13K	188.23K	0	50.81K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	100.7K	142.56K	102.31K	97.41K	0	0	0	0	572K
Current Ratio	0.18x	0.03x	0.06x	1.09x	0.63x	1.99x	28.78x	7.19x	13.80x	3.53x
Quick Ratio	0.18x	0.03x	0.06x	1.09x	0.63x	1.99x	28.78x	7.19x	12.95x	3.53x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	35.77K	43.26K	0	0	4.59M	3.86M	531K	0
Long-Term Debt	0	0	35.77K	43.26K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	11.51K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	4.59M	3.85M	531K	0
Total Liabilities	60.16K	599.52K	1.15M	943.7K	1.3M	811.04K	5.28M	5.37M	825.94K	757.99K
Total Debt+	0	124.13K	272.46K	43.26K	50.81K	0	0	77.44K	11.51K	38.78K
Net Debt	-762	107.36K	210.53K	-216.76K	-7.8K	-134.31K	-18.8M	-10.33M	-3.44M	-2.43M
Debt / Equity	-	-	-	0.13x	-	-	-	0.01x	0.00x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-47.00x	-30.36x	-51.90x	-11.73x	-81.09x	-657.17x	-	-	-
Total Equity+	119.93K	-317.06K	-654.63K	321.54K	-211.72K	985.16K	16.7M	6.97M	4.64M	3.34M
Equity Growth %	-	-3.64%	-1.06%	1.49%	-1.66%	5.65%	15.95%	-0.58%	-0.33%	-0.28%
Book Value per Share	1.59	-1.56	-3.10	0.55	-0.36	1.33	15.32	4.71	2.34	1.16
Total Shareholders' Equity	119.93K	-317.06K	-654.63K	321.54K	-211.72K	985.16K	16.7M	6.97M	4.64M	3.34M
Common Stock	0	0	0	5.86M	5.86M	6.48M	20.34M	15.18M	17.06M	18.49M
Retained Earnings	-413.68K	-1.88M	-2.35M	-6.13M	-6.76M	-6.3M	-10.09M	-14.13M	-17.85M	-21.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	354.81K	296.54K	581.49K	683K	0	6.44M	8.04M	-52.6K	-52.6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-106.8K	-107.78K	91.17K	-1.56M	-249.58K	-728.4K	-4.75M	-8.82M	-6.58M	-3.68M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.01%	1.85%	-18.06%	0.84%	-1.92%	-5.53%	-0.85%	0.25%	0.44%
Net Income	-36.92K	-414.83K	-474.2K	-3.78M	-629.58K	-1.28M	-1.3M	-6.99M	-2.16M	-3.31M
Depreciation & Amortization	0	16.02K	16.78K	19.32K	19.9K	20.44K	14.02K	55.46K	105.18K	117.27K
Stock-Based Compensation	0	203.88K	92.67K	275.09K	26.32K	230.12K	396.42K	487.94K	120.98K	122.53K
Deferred Taxes	0	1.75K	-1.24K	-46.93K	34.06K	-29.73K	-2.84M	-3.8M	0	0
Other Non-Cash Items	0	25.38K	219.2K	2.65M	1.64K	-90.17K	58.82K	3.7K	-3.62M	-721.9K
Working Capital Changes	-69.88K	61.77K	236.72K	-674.02K	298.08K	362.21K	-1.08M	1.45M	-1.03M	116.79K
Change in Receivables	1.58K	0	0	-20.06K	14.79K	-43K	-29.17K	-43.61K	21	43.07K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-30.17K	-24.56K	-12.48K	-154.81K	-7.04K	-14.35K	-31.22K	-44.22K	-46.36K	-38.92K
Capital Expenditures	-30.17K	-24.56K	-12.48K	-41.07K	-7.04K	-14.35K	-31.22K	-44.22K	-6	-38.92K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-11.31K	167.22K	0	0	0	0	-46.36K	0
Cash from Financing+	136.61K	115K	-33.52K	1.91M	55.21K	855.41K	19.18M	4.74M	-361.04K	2.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.67K	-157.91K	-113.04K	0	-14.79K	-184.58K	1.3M	1.4M	-294.95K	-651.31K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-136.97K	-132.34K	78.69K	-1.6M	-256.62K	-742.75K	-4.79M	-8.86M	-6.63M	-3.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.03%	1.59%	-21.29%	0.84%	-1.89%	-5.44%	-0.85%	0.25%	0.44%
FCF per Share	-1.81	-0.65	0.37	-2.73	-0.43	-1.00	-4.39	-5.99	-3.35	-1.29
FCF Conversion (FCF/Net Income)	2.89x	0.26x	-0.19x	0.41x	0.51x	0.72x	3.64x	1.26x	3.00x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.79%	-	-	-1174.33%	-884.2%	-260.74%	-14.78%	-59.12%	-37.83%	-119.41%
Return on Invested Capital (ROIC)	-	-	-	-828.37%	-	-260.34%	-	-	-	-255.76%
Debt / Equity	-	-	-	0.13x	-	-	-	0.01x	0.00x	0.01x
Interest Coverage	-	-47.00x	-30.36x	-51.90x	-11.73x	-81.09x	-657.17x	-	-	-
FCF Conversion	2.89x	0.26x	-0.19x	0.41x	0.51x	0.72x	3.64x	1.26x	3.00x	0.77x

Frequently Asked Questions

Growth & Financials

XORTX Therapeutics Inc. (XRTX) grew revenue by 0.0% over the past year. Growth has been modest.

XORTX Therapeutics Inc. (XRTX) reported a net loss of $1.9M for fiscal year 2024.

Dividend & Returns

XORTX Therapeutics Inc. (XRTX) has a return on equity (ROE) of -119.4%. Negative ROE indicates the company is unprofitable.

XORTX Therapeutics Inc. (XRTX) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

XORTX Therapeutics Inc. (XRTX) 10-Year Financial Performance & Capital Metrics

XRTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $0
EBITDA -$4M +41.2%
Net Income -$5M -116.8%
EPS (Diluted) -1.65 -52.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -119.41% -215.6%
ROIC -255.76%
Debt/Equity 0.01 +368.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 45.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-198.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM-214.13%

ROCE

10Y Avg-181.3%

5Y Avg-106.43%

3Y Avg-74.29%

Latest-84.46%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	19.32K	15.35K	16.04K	14.14K	55.52K	142.25K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-19.32K	-15.35K	-16.04K	-14.14K	-55.52K	-142.25K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	0.21%	-0.05%	0.12%	-2.93%	-1.56%	1%
Operating Expenses+	36.92K	405.34K	464.07K	1.16M	421.1K	1.08M	2.87M	9.82M	6.01M	3.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	36.92K	389.31K	380.92K	795.65K	390.33K	861.93K	2.2M	3.32M	3.55M	3.33M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	66.37K	342.25K	30.77K	217.78K	674.48K	6.5M	2.46M	264.29K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-2.64M	0	0	0	0	0	0
Operating Income+	-36.92K	-405.34K	-469.44K	-1.16M	-436.45K	-1.1M	-2.89M	-9.87M	-6.16M	-3.59M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-9.98%	-0.16%	-1.47%	0.62%	-1.51%	-1.63%	-2.42%	0.38%	0.42%
EBITDA+	-36.92K	-389.31K	-452.67K	-1.14M	-421.1K	-1.08M	-2.87M	-9.82M	-6.01M	-3.54M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-9.54%	-0.16%	-1.51%	0.63%	-1.56%	-1.66%	-2.42%	0.39%	0.41%
D&A (Non-Cash Add-back)	0	16.02K	16.78K	19.32K	15.35K	16.04K	14.14K	55.52K	142.25K	55.71K
EBIT	0	-405.34K	-443.88K	-1.09M	-456.81K	-997.72K	-1.3M	-7M	-2.2M	-3.76M
Net Interest Income+	0	0	0	0	-28.7K	-10.61K	-4.43K	101.49K	258.19K	175.26K
Interest Income	0	0	0	0	0	0	0	101.37K	257.65K	175.26K
Interest Expense	0	8.63K	15.46K	22.3K	37.21K	13.51K	4.39K	0	0	0
Other Income/Expense	0	-25.52K	-47.09K	-2.71M	-49.05K	87.43K	1.58M	2.88M	3.96M	-1.17M
Pretax Income+	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	8.63K	10.09K	22.3K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-10.24%	-0.14%	-6.96%	0.87%	-1.08%	-0.3%	-4.36%	0.69%	-1.17%
Net Income (Continuing)	-36.92K	-414.83K	-474.2K	-3.78M	-485.5K	-1.01M	-1.31M	-7M	-2.2M	-4.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.49	-2.05	-2.24	-6.45	-1.06	-1.73	-1.19	-4.72	-1.08	-1.65
EPS Growth %	-	-3.18%	-0.09%	-1.88%	0.84%	-0.63%	0.31%	-2.97%	0.77%	-0.53%
EPS (Basic)	-0.49	-2.05	-2.24	-6.45	-1.06	-1.73	-1.19	-4.72	-1.08	-1.65
Diluted Shares Outstanding	75.57K	202.74K	211.45K	584.99K	595.49K	740.45K	1.09M	1.48M	1.98M	2.88M
Basic Shares Outstanding	75.57K	202.74K	211.45K	584.99K	595.49K	740.45K	1.09M	1.48M	1.98M	2.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.94K	18.34K	63.55K	979.65K	815.25K	1.61M	20.12M	10.87M	4.07M	2.68M
Cash & Short-Term Investments	762	16.77K	61.94K	260.02K	58.61K	134.31K	18.8M	10.41M	3.45M	2.47M
Cash Only	762	16.77K	61.94K	260.02K	58.61K	134.31K	18.8M	10.41M	3.45M	2.47M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	10.17K	0	0	30.26K	0	11.25K	0	81.75K	60.71K	17.64K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	247.94K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	636.18	-
Other Current Assets	0	0	1.61K	689.37K	750.14K	0	764.31K	0	0	0
Total Non-Current Assets+	169.15K	264.13K	427.06K	285.59K	272.73K	183.75K	1.86M	1.48M	1.4M	1.42M
Property, Plant & Equipment	169.15K	0	1.12K	731	341	0	0	92.49K	23.93K	34.72K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	264.13K	258.71K	284.86K	272.39K	183.75K	255.59K	199.43K	175.25K	183.11K
Long-Term Investments	0	0	0	0	0	0	0	1.61M	1.58M	0
Other Non-Current Assets	0	0	167.22K	0	0	0	1.6M	1.18M	1.2M	1.2M
Total Assets+	180.09K	282.46K	490.6K	1.27M	1.09M	1.8M	21.98M	12.34M	5.47M	4.09M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.57%	0.74%	1.58%	-0.14%	0.65%	11.24%	-0.44%	-0.56%	-0.25%
Total Current Liabilities+	60.16K	599.52K	1.11M	900.45K	1.3M	811.04K	699.22K	1.51M	294.94K	757.99K
Accounts Payable	27.59K	159.67K	331.36K	304.5K	607.39K	305.83K	409.66K	1.29M	195.81K	84.02K
Days Payables Outstanding	-	-	-	5.75K	14.45K	6.96K	10.58K	8.5K	502.42	-
Short-Term Debt	0	124.13K	188.23K	0	50.81K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	100.7K	142.56K	102.31K	97.41K	0	0	0	0	572K
Current Ratio	0.18x	0.03x	0.06x	1.09x	0.63x	1.99x	28.78x	7.19x	13.80x	3.53x
Quick Ratio	0.18x	0.03x	0.06x	1.09x	0.63x	1.99x	28.78x	7.19x	12.95x	3.53x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	35.77K	43.26K	0	0	4.59M	3.86M	531K	0
Long-Term Debt	0	0	35.77K	43.26K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	11.51K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	4.59M	3.85M	531K	0
Total Liabilities	60.16K	599.52K	1.15M	943.7K	1.3M	811.04K	5.28M	5.37M	825.94K	757.99K
Total Debt+	0	124.13K	272.46K	43.26K	50.81K	0	0	77.44K	11.51K	38.78K
Net Debt	-762	107.36K	210.53K	-216.76K	-7.8K	-134.31K	-18.8M	-10.33M	-3.44M	-2.43M
Debt / Equity	-	-	-	0.13x	-	-	-	0.01x	0.00x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-47.00x	-30.36x	-51.90x	-11.73x	-81.09x	-657.17x	-	-	-
Total Equity+	119.93K	-317.06K	-654.63K	321.54K	-211.72K	985.16K	16.7M	6.97M	4.64M	3.34M
Equity Growth %	-	-3.64%	-1.06%	1.49%	-1.66%	5.65%	15.95%	-0.58%	-0.33%	-0.28%
Book Value per Share	1.59	-1.56	-3.10	0.55	-0.36	1.33	15.32	4.71	2.34	1.16
Total Shareholders' Equity	119.93K	-317.06K	-654.63K	321.54K	-211.72K	985.16K	16.7M	6.97M	4.64M	3.34M
Common Stock	0	0	0	5.86M	5.86M	6.48M	20.34M	15.18M	17.06M	18.49M
Retained Earnings	-413.68K	-1.88M	-2.35M	-6.13M	-6.76M	-6.3M	-10.09M	-14.13M	-17.85M	-21.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	354.81K	296.54K	581.49K	683K	0	6.44M	8.04M	-52.6K	-52.6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-106.8K	-107.78K	91.17K	-1.56M	-249.58K	-728.4K	-4.75M	-8.82M	-6.58M	-3.68M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.01%	1.85%	-18.06%	0.84%	-1.92%	-5.53%	-0.85%	0.25%	0.44%
Net Income	-36.92K	-414.83K	-474.2K	-3.78M	-629.58K	-1.28M	-1.3M	-6.99M	-2.16M	-3.31M
Depreciation & Amortization	0	16.02K	16.78K	19.32K	19.9K	20.44K	14.02K	55.46K	105.18K	117.27K
Stock-Based Compensation	0	203.88K	92.67K	275.09K	26.32K	230.12K	396.42K	487.94K	120.98K	122.53K
Deferred Taxes	0	1.75K	-1.24K	-46.93K	34.06K	-29.73K	-2.84M	-3.8M	0	0
Other Non-Cash Items	0	25.38K	219.2K	2.65M	1.64K	-90.17K	58.82K	3.7K	-3.62M	-721.9K
Working Capital Changes	-69.88K	61.77K	236.72K	-674.02K	298.08K	362.21K	-1.08M	1.45M	-1.03M	116.79K
Change in Receivables	1.58K	0	0	-20.06K	14.79K	-43K	-29.17K	-43.61K	21	43.07K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-30.17K	-24.56K	-12.48K	-154.81K	-7.04K	-14.35K	-31.22K	-44.22K	-46.36K	-38.92K
Capital Expenditures	-30.17K	-24.56K	-12.48K	-41.07K	-7.04K	-14.35K	-31.22K	-44.22K	-6	-38.92K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-11.31K	167.22K	0	0	0	0	-46.36K	0
Cash from Financing+	136.61K	115K	-33.52K	1.91M	55.21K	855.41K	19.18M	4.74M	-361.04K	2.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.67K	-157.91K	-113.04K	0	-14.79K	-184.58K	1.3M	1.4M	-294.95K	-651.31K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-136.97K	-132.34K	78.69K	-1.6M	-256.62K	-742.75K	-4.79M	-8.86M	-6.63M	-3.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.03%	1.59%	-21.29%	0.84%	-1.89%	-5.44%	-0.85%	0.25%	0.44%
FCF per Share	-1.81	-0.65	0.37	-2.73	-0.43	-1.00	-4.39	-5.99	-3.35	-1.29
FCF Conversion (FCF/Net Income)	2.89x	0.26x	-0.19x	0.41x	0.51x	0.72x	3.64x	1.26x	3.00x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.79%	-	-	-1174.33%	-884.2%	-260.74%	-14.78%	-59.12%	-37.83%	-119.41%
Return on Invested Capital (ROIC)	-	-	-	-828.37%	-	-260.34%	-	-	-	-255.76%
Debt / Equity	-	-	-	0.13x	-	-	-	0.01x	0.00x	0.01x
Interest Coverage	-	-47.00x	-30.36x	-51.90x	-11.73x	-81.09x	-657.17x	-	-	-
FCF Conversion	2.89x	0.26x	-0.19x	0.41x	0.51x	0.72x	3.64x	1.26x	3.00x	0.77x

Frequently Asked Questions

Growth & Financials

XORTX Therapeutics Inc. (XRTX) grew revenue by 0.0% over the past year. Growth has been modest.

XORTX Therapeutics Inc. (XRTX) reported a net loss of $1.9M for fiscal year 2024.

Dividend & Returns

XORTX Therapeutics Inc. (XRTX) has a return on equity (ROE) of -119.4%. Negative ROE indicates the company is unprofitable.

XORTX Therapeutics Inc. (XRTX) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.